Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 16/20 | 0.72 |
| ▸ | TMPRSS4 | Q9NRS4 | 12/20 | 0.71 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.69 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | IKBKB | O14920 | 1/20 | 0.69 |
| ▸ | CHUK | O15111 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 1/20 | 0.69 |
| ▸ | FLT3 | P36888 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | MYLK | Q15746 | 1/20 | 0.69 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.69 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130439 | 0.91 | P2RX1 (0.81) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL130730 | 0.86 | P2RX1 (0.73) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL16707261 | 0.85 | P2RX1 (0.71) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL23303456 | 0.84 | P2RX1 (1.00) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL132386 | 0.83 | P2RX1 (1.00) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL132474 | 0.82 | P2RX1 (1.00) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| Imd-0354 SCHEMBL29406220 | 0.82 | TMPRSS4 (1.00) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL130929 | 0.82 | P2RX1 (0.74) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| Imd-0354 SCHEMBL129165 | 0.82 | TMPRSS4 (1.00) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL130210 | 0.82 | P2RX1 (0.74) | P2RX1TMPRSS4P2RX7P2RX4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AEROMICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240360077-A1 | METHODS | AEROMICS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20220081391-A1 | METHODS | AEROMICS, INC. | 2022-03-17 | — | — | US | disclosed |
| CN-109512805-B | Compounds for the treatment of aquaporin mediated diseases | 埃罗米克斯公司 | 2021-12-31 | — | — | CN | disclosed |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AEROMICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20180334424-A1 | METHODS | AEROMICS, INC. | 2018-11-22 | — | — | US | disclosed |
| EP-2846787-B1 | Compounds for use in the treatment of aquaporin-mediated diseases | AEROMICS INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9994514-B2 | Methods of treating cerebral edema and spinal cord edema | AEROMICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9949991-B2 | Methods of treating aquaporin-mediated conditions | AEROMICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-1352650-B1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | INST MED MOLECULAR DESIGN INC (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334424-A1 | METHODS | AQP4, AQP1, AQP3 | P2RX1 2910/4885TMPRSS4 1257/4885P2RX7 2817/4885 |
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AQP4, AQP1, AQP3 | P2RX1 2714/4885TMPRSS4 1043/4885P2RX7 2687/4885 |
| US-20220081391-A1 | METHODS | AQP4, AQP1, AQP3 | P2RX1 2910/4885TMPRSS4 1257/4885P2RX7 2817/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | P2RX1 1459/4885TMPRSS4 1813/4885P2RX7 928/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | P2RX1 1538/4885TMPRSS4 1647/4885P2RX7 973/4885 |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AQP4, AQP1, AQP3 | P2RX1 2805/4885TMPRSS4 946/4885P2RX7 2680/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | P2RX1 1538/4885TMPRSS4 1647/4885P2RX7 973/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | P2RX1 1538/4885TMPRSS4 1647/4885P2RX7 973/4885 |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AQP4, AQP1, AQP3 | P2RX1 3317/4885TMPRSS4 1444/4885P2RX7 3316/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | P2RX1 2316/4885TMPRSS4 3292/4885P2RX7 1605/4885 |
| US-20240360077-A1 | METHODS | AQP4, AQP1, AQP3 | P2RX1 2797/4885TMPRSS4 1415/4885P2RX7 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.